ABS-201 (Absci) for Hair Loss: What the Evidence Shows So Far

ABS-201 is Absci’s investigational antibody for pattern hair loss. It targets the prolactin receptor, giving researchers a way to investigate hair growth beyond treatments that reduce DHT. Human scalp-tissue experiments and early clinical findings have made it a drug worth following. Its next important test is whether the ongoing HEADLINE study can show a meaningful improvement in hair growth in people.^[1,2]

For someone losing hair, the practical questions come first. Is it a tablet or an injection? Could it help women? What are the risks, and how many years might it take to become available?

There are useful answers to some of those questions already. Others depend on results we have yet to see.

Latest updates

As of 29 September 2026: ABS-201 remains investigational. The public clinical findings reviewed for this article concern early safety and drug exposure; controlled human hair-growth results have not yet been reported in those sources.

Why ABS-201 is attracting attention

The strongest argument for ABS-201 has three parts.

First, it addresses a different biological target. A treatment acting through prolactin-receptor signaling could expand the options for people whose current treatment is unsuitable or gives an incomplete response. That possibility also makes the research relevant to women, although response in either group still needs to be established.

Second, the rationale includes experiments in human scalp tissue. Researchers have examined changes in the hair cycle, follicular cells and growth-related signals, providing a more specific basis for clinical testing than a mechanism proposed only on paper.^[7,8]

Third, Absci is investigating a long-acting antibody. If infrequent injections eventually produced a worthwhile benefit with acceptable safety, that could matter to patients who find daily treatment difficult. The company has described a possible schedule of two or three injections over six months. This remains a development target.^[3,4]

These are good reasons to pay attention. How much hair grows, who benefits and what treatment requires will determine whether that interest translates into a useful clinical option.

What the prolactin and scalp-tissue research shows

Prolactin is usually discussed as a pituitary hormone, but human hair follicles also produce it and express its receptor. In a 2006 laboratory study, exposing cultured scalp follicles to high concentrations of prolactin reduced hair-shaft elongation and encouraged an earlier transition into catagen, the regression stage of the hair cycle.^[6]

ABS-201 is designed to block the receptor through which prolactin signals. Describing it simply as a drug that “lowers prolactin” misses that distinction. Local follicular signaling and a blood prolactin measurement are also different things; neither a normal nor a raised blood result is currently an established test for predicting response to this antibody.^[1,6]

Can prolactin blockade help a miniaturized follicle recover?

The ABS-201 preclinical findings are more detailed than the phrase “promising laboratory results” suggests.

Absci’s December 2025 announcement described human scalp experiments in which ABS-201 blocked prolactin-related STAT5 activation, helped maintain anagen—the growth phase—and reduced the shift toward catagen. The reported findings also included:

• Less apoptosis, or programmed cell death, in K15-positive cells in the follicular stem-cell region.
• Greater proliferation and generation of CD34-positive progeny.
• Increased matrix-cell proliferation and expression of the growth-related signals IGF-1 and FGF7.^[7]

A research-team abstract presented at Cold Spring Harbor in May 2026 describes six-day experiments using male frontotemporal scalp tissue in organ culture, with antibody and control conditions. Activity was reported both with and without added prolactin. This is primary preclinical evidence, presented as a conference abstract; it is not a clinical hair-growth trial.^[8]

An earlier human tissue study by Garza and colleagues helps explain the interest in these cell populations. Balding scalp retained follicular stem cells but had fewer cells in certain progenitor populations. That makes follicular recovery biologically interesting, while leaving open which interventions can achieve it in patients.^[9]

The work concerns cells within existing follicles. For patients, the question is whether a miniaturized follicle can produce thicker hair over repeated growth cycles, enough to improve scalp coverage.

Where does this leave DHT?

The androgen pathway remains relevant. Randomized finasteride trials in men have shown improved hair outcomes compared with placebo, including follow-up into a second year.^[10]

A follicle responds to several signals. A successful prolactin-receptor treatment could add another option without making androgen-based treatment obsolete. Whether the approaches work better together would require combination studies.

Our explanation of how finasteride works for hair loss covers the established mechanism in more detail.

How ABS-201 is given and what HEADLINE has reported

ABS-201 is an injectable antibody, not a tablet. HEADLINE separates initial single-dose testing from repeated-dose treatment.

These are research regimens, not instructions for treatment.^[2,3]

HEADLINE is a randomized, blinded, placebo-controlled Phase 1/2a study. Its registered objectives include safety, drug exposure, immune responses to the antibody, and changes in hair count and width over 26 weeks. The registry lists planned enrollment of up to 227 participants.^[2]

The June interim announcement covered 32 healthy adult participants across the four blinded single-dose cohorts, including placebo recipients. At the 8 June data cutoff, no serious adverse events had been reported. Events were mild apart from one moderate headache assessed as unlikely to be related to treatment. Absci estimated a half-life of at least 65 days.^[3]

A long half-life means the antibody leaves the body slowly. That may allow longer intervals between doses; it also makes follow-up after dosing important.

Absci has also used modeling to describe predicted prolactin-receptor occupancy above 90%. “Predicted” is doing meaningful work in that sentence. This is a pharmacological projection, rather than a demonstrated threshold at which patients regrow hair.^[1]

HMI-115 and the larger hair-loss trial

HMI-115 is a different antibody targeting the same receptor. It matters because it provides human evidence about the pathway, including a larger controlled hair-loss study.

In January 2024, Hope Medicine announced results from a small, open-label Phase Ib study involving 12 men and four women. The company reported an average increase of 14 non-vellus hairs per square centimeter from baseline in the male group at 24 weeks. Without a placebo comparison, that result was an early signal rather than a reliable estimate of the treatment effect.^[11]

The subsequent AGA Phase 2 study, NCT06118866, is the more important controlled test. Its current registry entry records 192 male participants, randomized and blinded treatment, three subcutaneous HMI-115 regimens, and a placebo group. The primary hair-count assessment was at 24 weeks. The study is listed as completed on 28 November 2024.^[12]

However, the registry did not contain posted results when checked for this article; its last update was dated 4 June 2025. Completion alone therefore leaves the central question unanswered. We need the results, the treatment-versus-placebo difference and the safety findings.

This study could help clarify whether prolactin-receptor blockade improves hair growth in AGA. Its findings will describe HMI-115 at the doses tested. ABS-201 is being evaluated in a separate program with its own dosing and exposure profile.

What this could mean for women

A target outside the androgen pathway is a reasonable source of interest in female pattern hair loss. It creates another possibility to investigate, particularly where existing options are unsuitable or insufficient. It does not yet identify which women would benefit.

The early HMI-115 hair study included only four women, too few to establish a dependable female treatment effect, and the larger Phase 2 hair study enrolled men only. HEADLINE’s general eligibility includes men and women, while its AGA criteria specify a Norwood–Hamilton pattern.^[2,11,12]

For women considering treatment, the useful evidence would come from a clearly defined female pattern hair-loss group large enough to assess benefit against a control. Hormonal or menopausal characteristics and adverse events would help show whom the findings apply to.

HMI-115’s endometriosis program adds a different kind of information: repeated prolactin-receptor blockade has been studied in premenopausal women. That is relevant human exposure and safety context, although the condition, antibody and outcome differ from ABS-201 treatment for hair loss.^[13,14]

Pregnancy and breastfeeding are excluded from HEADLINE. Nothing in the evidence discussed here establishes ABS-201 as suitable during either.^[2]

Safety evidence from both antibodies

For ABS-201 itself, the public interim safety findings described above come from an early, small study. They support continued investigation; larger groups and longer follow-up are needed to characterize less common or delayed problems.

For the broader mechanism, there is more human evidence than the ABS-201 announcement alone.

A randomized HMI-115 endometriosis Phase 2 study was published in The Lancet Obstetrics, Gynaecology, & Women’s Health in 2025. It studied repeated subcutaneous treatment in premenopausal women.^[13]

The trial registry records 142 randomized participants; its posted adverse-event tables cover a 108-person analysis population. Treatment lasted 12 weeks, while adverse-event collection extended through study participation, approximately 34 weeks. The table below reproduces the registry’s non-serious adverse-event counts, not a claim that every event was caused by treatment.^[14]

Reported events included injection-site reactions and headaches. Amenorrhea, the absence of periods, was recorded in four participants who received HMI-115 and in none of those given placebo. One serious event, a breast mass, appears in the 240 mg group.^[14] The sponsor’s publication summary states that there were no treatment-related serious adverse events or deaths. The registry records events that occurred during follow-up; the sponsor’s statement addresses their assessed relationship to treatment.^[13]

The endometriosis program gives researchers experience with repeated receptor blockade in premenopausal women. For hair-loss treatment, longer follow-up with ABS-201 will help establish how patients tolerate its own doses and duration of exposure.

Hope Medicine subsequently announced FDA Fast Track designation for HMI-115 in endometriosis-associated pain, and an endometriosis Phase 3 trial is now registered as recruiting, with a January 2026 start.^[15,16] Fast Track facilitates development and regulatory communication; it is not marketing approval, and this designation does not apply to ABS-201 for hair loss.^[17]

Results, approval and a realistic timeline

For ABS-201 hair loss, Absci’s August 2026 guidance points to an interim readout in the second half of 2026 and full 26-week results in early 2027. Those are research milestones.^[4]

There is a documented reason to treat the dates as estimates. In November and December 2025, Absci projected a fourth-quarter 2026 start for the same molecule’s endometriosis Phase 2 program. Its first- and second-quarter 2026 updates repeated that forecast. On 24 September 2026, the projected start became mid-2027.^[4,5,18]

The hair-loss readout guidance has remained consistent in the updates reviewed. The endometriosis start moved by roughly two to three quarters within about ten months. The distinction matters: the revised date concerns another indication, so it is not evidence that the hair-loss program has missed its own readout. It does show why a patient should avoid building a treatment plan around a projected development date.

How many years might approval take?

There is no defensible launch year to give yet. Successful early results would still leave pivotal clinical evidence, sufficient safety follow-up, manufacturing requirements and regulatory review.

A separate new Phase 2 is not an automatic next step: Absci has discussed a possible transition from HEADLINE’s Phase 1/2a directly to Phase 3, depending on the data and regulatory discussions.^[20]

For scale, the FDA describes Phase 3 research in general as commonly lasting one to four years. That is background about drug development, not a forecast for ABS-201. Submission and regulatory review follow the necessary evidence, and approval is not guaranteed.^[19]

From this stage, a multi-year horizon is more realistic than expecting routine access within a few months. That is an inference from the remaining work. A confirmed pivotal-trial plan and more mature results would make a narrower estimate possible.

Where ABS-201 sits among other treatments in development

ABS-201 is part of a wider research pipeline.

Other approaches have already reached larger or later-stage trials. Cosmo reported 12-month Phase 3 findings in April 2026 for topical clascoterone 5%, an androgen-receptor antagonist studied in men. Veradermics’ August update described late-stage trials of VDPHL01, an extended-release oral minoxidil formulation: a confirmatory Phase 3 study in men and a Phase 2/3 study in women.^[21,22]

These programs work differently and have different administration and safety considerations. Development phase helps explain maturity of evidence; it does not produce an efficacy ranking across unrelated studies. Comparing headline percentages without matching populations, endpoints and follow-up would be misleading.

The attraction of ABS-201 is the additional target it explores.

The results that would change a treatment decision

When the next HEADLINE data arrive, these are the questions that will matter clinically:

An average increase is a useful starting point, but it can hide substantial differences between patients. A statistically detectable change may also be difficult to notice in the mirror. Consistent lighting, hair length, positioning and assessment methods make photographs easier to interpret.

An interim signal could be encouraging before every durability question is settled. The appropriate response would be to update the assessment as the evidence develops.

For someone deciding what to do now, the starting point is their diagnosis and response to current treatment. An individualized plan can be reviewed as new evidence becomes available. Our guide to a long-term hair-loss treatment plan explains how to approach that decision over time. Patients who want to discuss their current situation can contact Pure Line.

Frequently asked questions

— Dr. Mesut Demir